A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,442 · see citing works

Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing

Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775 · see citing works

The polycomb group protein EZH2 is involved in progression of prostate cancer

Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717 · see citing works

An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors

Ben‐Porath, I., Thomson, M., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008) · Nature Genetics · doi:10.1038/ng.127 · Cited by 2,523 · see citing works

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

Morin, R. D., Johnson, N. A., Severson, T., Mungall, A. J. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F. C., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,670 · see citing works

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649 · see citing works

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614 · see citing works

Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein

Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596 · see citing works

UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development

Agger, K., Cloos, P. A., Christensen, J. F., Pasini, D., Rose, S., Rappsilber, J., Issaeva, I., Canaani, E., Salcini, A. E., & Helin, K. (2007) · Nature · doi:10.1038/nature06145 · Cited by 1,392 · see citing works

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346 · see citing works

Role of the polycomb protein EED in the propagation of repressive histone marks

Margueron, R., Justin, N., Ohno, K., Sharpe, M. L., Son, J., Drury, W. J., Voigt, P., Martin, S. R., Taylor, W. R., Marco, V. D., et al. (2009) · Nature · doi:10.1038/nature08398 · Cited by 1,203 · see citing works

EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.

Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196 · see citing works

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139 · see citing works

Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists.

Copeland, R. A. (2005) · PubMed · Cited by 1,045 · see citing works

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Lohr, J. G., Stojanov, P., Lawrence, M. S., Auclair, D., Chapuy, B., Sougnez, C. L., Cruz‐Gordillo, P., Knoechel, B., Asmann, Y. W., Slager, S. L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121343109 · Cited by 977 · see citing works

The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing

De Santa, F., Totaro, M. G., Prosperini, E., Notarbartolo, S., Testa, G., & Natoli, G. (2007) · Cell · doi:10.1016/j.cell.2007.08.019 · Cited by 965 · see citing works

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J. J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.009 · Cited by 926 · see citing works

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q. (2007) · Genes & Development · doi:10.1101/gad.1524107 · Cited by 895 · see citing works

Roles of the EZH2 histone methyltransferase in cancer epigenetics

Simon, J. A., & Lange, C. A. (2008) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2008.07.010 · Cited by 860 · see citing works

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

van Haaften, G., Dalgliesh, G. L., Davies, H., Chen, L., Bignell, G., Greenman, C., Edkins, S., Hardy, C., O'Meara, S., Teague, J., et al. (2009) · Nature Genetics · doi:10.1038/ng.349 · Cited by 784 · see citing works

A histone H3 lysine 27 demethylase regulates animal posterior development

Lan, F., Bayliss, P. E., Rinn, J. L., Whetstine, J. R., Wang, J. K., Chen, S., Iwase, S., Alpatov, R., Issaeva, I., Canaani, E., et al. (2007) · Nature · doi:10.1038/nature06192 · Cited by 782 · see citing works

Demethylation of H3K27 Regulates Polycomb Recruitment and H2A Ubiquitination

Lee, M. G., Villa, R., Trojer, P., Norman, J. A., Yan, K.-P., Reinberg, D., Croce, L. D., & Shiekhattar, R. (2007) · Science · doi:10.1126/science.1149042 · Cited by 772 · see citing works

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

Nikoloski, G., Langemeijer, S. M. C., Kuiper, R. P., Knops, R., Massop, M., Tönnissen, E., van der Heijden, A., Scheele, T. N., Vandenberghe, P., de Witte, T., et al. (2010) · Nature Genetics · doi:10.1038/ng.620 · Cited by 754 · see citing works

Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases

Hong, S., Cho, Y., Yu, L., Yu, H., Veenstra, T. D., & Ge, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707292104 · Cited by 700 · see citing works

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

Sneeringer, C. J., Scott, M. P., Kuntz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., & Copeland, R. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012525107 · Cited by 691 · see citing works

Evaluation of Enzyme Inhibitors in Drug Discovery

Copeland, R. A. (2013) · Wiley eBooks · doi:10.1002/9781118540398 · Cited by 689 · see citing works

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation

Yap, D., Chu, J., Berg, T., Schapira, M., Cheng, S., Moradian, A., Morin, R. D., Mungall, A. J. J., Meissner, B., Boyle, M., et al. (2010) · Blood · doi:10.1182/blood-2010-11-321208 · Cited by 609 · see citing works

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation

Miranda, T. B., Cortez, C. C., Yoo, C. B., Liang, G., Abe, M., Kelly, T. K., Márquez, V. E., & Jones, P. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0013 · Cited by 588 · see citing works

A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells

Vedadi, M., Baršytė-Lovejoy, D., Liu, F., Rival‐Gervier, S., Allali‐Hassani, A., Labrie, V., Wigle, T. J., DiMaggio, P. A., Wasney, G. A., Siarheyeva, A., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.599 · Cited by 547 · see citing works

Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia

Ntziachristos, P., Tsirigos, A., Vlierberghe, P. V., Nedjic, J., Trimarchi, T., Flaherty, M. S., Ferrés-Marcó, D., Ros, V. G. D., Tang, Z., Siegle, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2651 · Cited by 528 · see citing works

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

McCabe, M. T., Graves, A. P., Ganji, G., Diaz, E., Halsey, W. S., Jiang, Y., Smitheman, K. N., Ott, H. M., Pappalardi, M. B., Allen, K. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116418109 · Cited by 493 · see citing works

Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27Preprint

Kirmizis, A., Reinberg, D., Farnham, P., Margueron, R., Reinberg, D., Green, R., & Farnham, P. J. (2004) · Genes & Development · doi:10.1101/gad.1200204 · Cited by 493 · see citing works

Protein methyltransferases as a target class for drug discovery

Copeland, R. A., Solomon, M. E., & Richon, V. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2974 · Cited by 467 · see citing works

How many mutations are required for tumorigenesis? implications from human cancer data

Balmain, A., Barrett, J. C., Moses, H. L., & Renan, M. J. (1993) · Molecular Carcinogenesis · doi:10.1002/mc.2940070303 · Cited by 463 · see citing works

EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis

Velichutina, I., Shaknovich, R., Geng, H., Johnson, N. A., Gascoyne, R. D., Melnick, A. M., & Elemento, O. (2010) · Blood · doi:10.1182/blood-2010-04-280149 · Cited by 299 · see citing works

Studies on liver alcohol dehydrogenase complexes

Yonetani, T., & Theorell, H. (1964) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(64)90184-5 · Cited by 282 · see citing works

Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

Dornan, D., Bennett, F. L., Chen, Y., Dennis, M. S., Eaton, D., Elkins, K., French, D. M., Go, M. A. T., Jack, A., Junutula, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-02-205500 · Cited by 273 · see citing works

Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2)

Xu, C., Bian, C., Yang, W., Galka, M., Ouyang, H., Chen, C., Qiu, W., Liu, H., Jones, A. E., MacKenzie, F., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008937107 · Cited by 221 · see citing works

Chemogenetic Analysis of Human Protein Methyltransferases

Richon, V. M., Johnston, D., Sneeringer, C. J., Jin, L., Majer, C. R., Elliston, K. O., Jerva, L. F., Scott, M. P., & Copeland, R. A. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01135.x · Cited by 191 · see citing works

Structural Basis of EZH2 Recognition by EED

Han, Z., Xing, X., Hu, M., Zhang, Y., Liu, P., & Chai, J. (2007) · Structure · doi:10.1016/j.str.2007.08.007 · Cited by 150 · see citing works

A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers

Wang, S., Robertson, G. P., & Zhu, J. (2004) · Gene · doi:10.1016/j.gene.2004.09.006 · Cited by 96 · see citing works

The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states

Wigle, T. J., Knutson, S. K., Jin, L., Kuntz, K. W., Pollock, R. M., Richon, V. M., Copeland, R. A., & Scott, M. P. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.018 · Cited by 92 · see citing works

Choosing anticancer drug targets in the postgenomic era

Kaelin, W. G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8888 · Cited by 79 · see citing works

Kinase Inhibitor Drugs

(2009) · Wiley eBooks · doi:10.1002/9780470524961 · Cited by 60 · see citing works

Protein methyltransferase inhibitors as personalized cancer therapeutics

Copeland, R. A. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.08.001 · Cited by 19 · see citing works

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · see citing works

Targeting EZH2 in cancer

Kim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471 · see citing works

Transcriptional enhancers: from properties to genome-wide predictions

Shlyueva, D., Stampfel, G., & Stark, A. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3682 · Cited by 1,356 · see citing works

The epigenetics of epithelial-mesenchymal plasticity in cancer

Tam, W. L., & Weinberg, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3336 · Cited by 1,159 · see citing works

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097 · see citing works

EZH2: a novel target for cancer treatment

Duan, R., Du, W., & Guo, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00937-8 · Cited by 946 · see citing works

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

Béguelin, W., Popovic, R., Teater, M. R., Jiang, Y., Bunting, K. L., Rosen, M., Shen, H., Yang, S. N., Wang, L., Ezponda, T., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.011 · Cited by 854 · see citing works

Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells

Kim, E. H., Kim, M., Woo, D., Shin, Y., Shin, J., Chang, N., Oh, Y. T., Kim, H., Rheey, J., Nakano, I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.008 · Cited by 811 · see citing works

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

Knutson, S. K., Warholic, N. M., Wigle, T. J., Klaus, C. R., Allain, C. J., Raimondi, A., Scott, M. P., Chesworth, R., Moyer, M. P., Copeland, R. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303800110 · Cited by 794 · see citing works

Metabolic reprogramming and epigenetic modifications on the path to cancer

Sun, L., Zhang, H., & Gao, P. (2021) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 796 · see citing works

Occupying Chromatin: Polycomb Mechanisms for Getting to Genomic Targets, Stopping Transcriptional Traffic, and Staying Put

Simon, J. A., & Kingston, R. E. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.02.013 · Cited by 727 · see citing works

The SWI/SNF complex in cancer — biology, biomarkers and therapy

Mittal, P., & Roberts, C. W. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0357-3 · Cited by 705 · see citing works

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

Bitler, B. G., Aird, K. M., Гарипов, А. Р., Li, H., Amatangelo, M. D., Kossenkov, A. V., Schultz, D., Liu, Q., Shih, I., Conejo-Garcia, J. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3799 · Cited by 683 · see citing works

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Italiano, A., Soria, J., Toulmonde, M., Michot, J., Lucchesi, C., Varga, A., Coindre, J., Blakemore, S. J., Clawson, A., Suttle, B. B., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30145-1 · Cited by 637 · see citing works

Medicinal chemistry of indole derivatives: Current to future therapeutic prospectives

Kumari, A., & Singh, R. K. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103021 · Cited by 596 · see citing works

Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host

Timp, W., & Feinberg, A. (2013) · Nature Reviews. Cancer · doi:10.1038/nrc3486 · Cited by 586 · see citing works

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Chan-Penebre, E., Kuplast, K. G., Majer, C. R., Boriack-Sjodin, P. A., Wigle, T. J., Johnston, L. D., Rioux, N., Munchhof, M. J., Jin, L., Jacques, S. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1810 · Cited by 569 · see citing works

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., Zeng, J., Li, M., Fan, H. X., Lin, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210371110 · Cited by 550 · see citing works

The roles of DNA, RNA and histone methylation in ageing and cancer

Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549 · see citing works

EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas

Mohammad, F., Weissmann, S., Leblanc, B., Pandey, D. P., Højfeldt, J. W., Comet, I., Zheng, C., Johansen, J. V., Rapin, N., Porse, B. T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4293 · Cited by 535 · see citing works

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma

Knutson, S. K., Kawano, S., Minoshima, Y., Warholic, N. M., Huang, K., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0773 · Cited by 529 · see citing works

Epigenetic balance of gene expression by Polycomb and COMPASS families

Piunti, A., & Shilatifard, A. (2016) · Science · doi:10.1126/science.aad9780 · Cited by 524 · see citing works

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Mohammad, H. P., Smitheman, K. N., Kamat, C. D., Soong, D., Federowicz, K., Aller, G. S. V., Schneck, J., Carson, J. D., Liu, Y., Butticello, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.002 · Cited by 514 · see citing works

Germinal centres and B cell lymphomagenesis

Basso, K., & Dalla-Favera, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3814 · Cited by 510 · see citing works

Emerging Roles for Branched-Chain Amino Acid Metabolism in Cancer

Sivanand, S., & Heiden, M. G. V. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.011 · Cited by 488 · see citing works

Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis

Zhang, J., Dominguez-Sola, D., Hussein, S., Lee, J., Holmes, A. B., Bansal, M., Vlasevska, S., Mo, T., Tang, H., Basso, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3940 · Cited by 463 · see citing works

An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1

Konze, K. D., Ma, A., Li, F., Baršytė-Lovejoy, D., Parton, T., MacNevin, C. J., Liu, F., Gao, C., Huang, X., Kuznetsova, E., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400133j · Cited by 450 · see citing works

Chromatin proteins and modifications as drug targets

Helin, K., & Dhanak, D. (2013) · Nature · doi:10.1038/nature12751 · Cited by 435 · see citing works

Maintaining cell identity: PRC2-mediated regulation of transcription and cancer

Comet, I. V., Riising, E. M., Leblanc, B., & Helin, K. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.83 · Cited by 428 · see citing works

Structural insights into conformational stability of both wild-type and mutant EZH2 receptor

Aier, I., Varadwaj, P. K., & Raj, U. (2016) · Scientific Reports · doi:10.1038/srep34984 · Cited by 435 · see citing works

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

Gan, L., Yang, Y., Li, Q., Feng, Y., Liu, T., & Guo, W.-J. (2018) · Biomarker Research · doi:10.1186/s40364-018-0122-2 · Cited by 428 · see citing works

Diffuse large B-cell lymphoma—treatment approaches in the molecular era

Roschewski, M. J., Staudt, L. M., & Wilson, W. H. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.197 · Cited by 413 · see citing works

SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2

Kim, K. H., Kim, W., Howard, T. P., Vázquez, F., Tsherniak, A., Wu, J. N., Wang, W., Haswell, J. R., Walensky, L. D., Hahn, W. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3968 · Cited by 407 · see citing works

Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy

Morera, L., Lübbert, M., & Jung, M. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0223-4 · Cited by 396 · see citing works

Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy

Biswas, S., & Rao, C. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.021 · Cited by 402 · see citing works

Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo

Borkin, D., He, S., Miao, H., Kempińska, K., Pollock, J., Chase, J., Purohit, T., Malik, B., Zhao, T., Wang, J.-Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.016 · Cited by 350 · see citing works

The roles of Polycomb repressive complexes in mammalian development and cancer

Piunti, A., & Shilatifard, A. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00341-1 · Cited by 382 · see citing works

Critical roles of non-histone protein lysine methylation in human tumorigenesis

Hamamoto, R., Saloura, V., & Nakamura, Y. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3884 · Cited by 376 · see citing works

Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2

Verma, S. K., Tian, X., LaFrance, L. V., Duquenne, C., Suarez, D., Newlander, K. A., Romeril, S. P., Burgess, J. L., Grant, S. W., Brackley, J. A., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3003346 · Cited by 374 · see citing works

Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation

Pan, M., Reid, M. A., Lowman, X. H., Kulkarni, R. P., Tran, T. Q., Liu, X., Yang, Y., Hernandez-Davies, J. E., Rosales, K. K., Li, H., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3410 · Cited by 368 · see citing works

Epigenetic Therapeutics: A New Weapon in the War Against Cancer

Ahuja, N., Sharma, A. R., & Baylin, S. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-035900 · Cited by 364 · see citing works

Targeting Transcription Factors for Cancer Treatment

Lambert, M., Jambon, S., Depauw, S., & David‐Cordonnier, M. (2018) · Molecules · doi:10.3390/molecules23061479 · Cited by 351 · see citing works

Chromatin repressive complexes in stem cells, development, and cancer

Laugesen, A., & Helin, K. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.05.006 · Cited by 352 · see citing works

Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer

Kim, W., Bird, G. H., Neff, T., Guo, G., Kerényi, M., Walensky, L., & Orkin, S. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1331 · Cited by 357 · see citing works

WD40 repeat domain proteins: a novel target class?

Schapira, M., Tyers, M., Torrent, M., & Arrowsmith, C. H. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.179 · Cited by 335 · see citing works

Inhibitors of Protein Methyltransferases and Demethylases

Kanıskan, H. Ü., Martini, M. L., & Jin, J. J. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00801 · Cited by 320 · see citing works

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED

Qi, W., Zhao, K., Gu, J., Huang, Y., Wang, Y., Zhang, H., Zhang, M., Zhang, J., Yu, Z., Li, L., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2304 · Cited by 316 · see citing works

Poised epigenetic states and acquired drug resistance in cancer

Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301 · see citing works

Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia

Wouters, B. J., & Delwel, R. (2015) · Blood · doi:10.1182/blood-2015-07-604512 · Cited by 293 · see citing works

Regulation and Role of EZH2 in Cancer

Yamaguchi, H., & Hung, M. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.46.3.209 · Cited by 291 · see citing works

Chemical and Biochemical Perspectives of Protein Lysine Methylation

Luo, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00008 · Cited by 288 · see citing works

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)

He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283 · see citing works

Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP

Liu, F., Baršytė-Lovejoy, D., Li, F., Xiong, Y., Korboukh, V. K., Huang, X., Allali‐Hassani, A., Janzen, W. P., Roth, B. L., Frye, S. V., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401480r · Cited by 285 · see citing works

Genetics of diffuse large B-cell lymphoma

Pasqualucci, L., & Dalla‐Favera, R. (2018) · Blood · doi:10.1182/blood-2017-11-764332 · Cited by 284 · see citing works

A new world of Polycombs: unexpected partnerships and emerging functions

Schwartz, Y. B., & Pirrotta, V. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3603 · Cited by 277 · see citing works

Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors

Huang, X., Yan, J., Zhang, M., Wang, Y., Chen, Y., Fu, X., Wei, R., Zheng, X., Liu, Z., Zhang, X., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.058 · Cited by 271 · see citing works

Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis

Cagánová, M., Carrisi, C., Varano, G., Mainoldi, F., Zanardi, F., Germain, P., George, L. A., Alberghini, F., Ferrarini, L., Talukder, A. K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70626 · Cited by 256 · see citing works

EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis

Béguelin, W., Teater, M., Gearhart, M. D., Calvo Fernández, M. T., Goldstein, R. L., Cárdenas, M. G., Hatzi, K., Rosen, M., Shen, H., Corcoran, C. M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.07.006 · Cited by 254 · see citing works

Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia

Abdel-Wahab, O. I., & Levine, R. L. (2013) · Blood · doi:10.1182/blood-2013-01-451781 · Cited by 248 · see citing works

Targeting Epigenetics in Cancer

Bennett, R. L., & Licht, J. D. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-105106 · Cited by 252 · see citing works

Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease

Bhat, K. P., Kanıskan, H. Ü., Jin, J. J., & Gozani, O. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00108-x · Cited by 243 · see citing works

Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM

Wong, A. S. L., Choi, G. C. G., Cui, C. H., Pregernig, G., Milani, P., Adam, M., Perli, S. D., Kazer, S. W., Gaillard, A., Hermann, M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517883113 · Cited by 236 · see citing works

Epigenetics in cancer: Fundamentals and Beyond

Biswas, S., & Rao, C. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.011 · Cited by 243 · see citing works

Discovery of a first-in-class EZH2 selective degrader

Ma, A., Στρατικόπουλος, Η., Park, K., Wei, J., Martin, T. C., Yang, X., Schwarz, M. C., Leshchenko, V. V., Rialdi, A., Dale, B., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0421-4 · Cited by 240 · see citing works

EZH2: biology, disease, and structure-based drug discovery

Tan, J., Yan, Y., Wang, X., Jiang, Y., & Xu, H. E. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.161 · Cited by 234 · see citing works

AMPK improves gut epithelial differentiation and barrier function via regulating Cdx2 expression

Sun, X., Yang, Q., Rogers, C. J., Du, ‬., & Zhu, M. J. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.14 · Cited by 233 · see citing works

O-GlcNAcylation regulates EZH2 protein stability and function

Chu, C.-S., Lo, P.-W., Yeh, Y.-H., Hsu, P., Peng, S.-H., Teng, Y., Kang, M.-L., Wong, C., & Juan, L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323226111 · Cited by 231 · see citing works

Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia

Xu, B., On, D. M., Ma, A., Parton, T., Konze, K. D., Pattenden, S. G., Allison, D. F., Cai, L., Rockowitz, S., Liu, S., et al. (2014) · Blood · doi:10.1182/blood-2014-06-581082 · Cited by 229 · see citing works

Targeting tumour-supportive cellular machineries in anticancer drug development

Dobbelstein, M., & Moll, U. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 229 · see citing works

Regulatory Enhancer–Core-Promoter Communication via Transcription Factors and Cofactors

Zabidi, M. A., & Stark, A. (2016) · Trends in Genetics · doi:10.1016/j.tig.2016.10.003 · Cited by 228 · see citing works

Identification of ( R )- N -((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1 H -indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas

Vaswani, R. G., Gehling, V. S., Dakin, L. A., Cook, A. S., Nasveschuk, C. G., Duplessis, M., Iyer, P., Balasubramanian, S., Zhao, F., Good, A. C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01315 · Cited by 226 · see citing works

Targeting EZH2 in cancer therapy

Yamagishi, M., & Uchimaru, K. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000390 · Cited by 224 · see citing works

The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex

He, Y., Selvaraju, S., Curtin, M. L., Jakob, C. G., Zhu, H., Comess, K. M., Shaw, B., The, J., Lima-Fernandes, E., Szewczyk, M. M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2306 · Cited by 224 · see citing works

Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches

Uddin, M. S., Mamun, A. A., Alghamdi, B. S. A., Tewari, D., Jeandet, P., Sarwar, M. S., & Ashraf, G. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.015 · Cited by 215 · see citing works

Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and CancerPreprint

Laugesen, A., Højfeldt, J. W., & Helin, K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026575 · Cited by 214 · see citing works

Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2

Ler, L. D., Ghosh, S., Chai, X., Thike, A. A., Heng, H. L., Siew, E. Y., Dey, S., Koh, L. K., Lim, J. Q., Lim, W. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8312 · Cited by 208 · see citing works

Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6

Kerres, N., Steurer, S., Schlager, S., Bader, G., Berger, H., Caligiuri, M., Dank, C., Engen, J. R., Ettmayer, P., Fischerauer, B., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.081 · Cited by 207 · see citing works

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy

Emran, A. A., Chatterjee, A., Rodger, E. J., Tiffen, J. C., Gallagher, S. J., Eccles, M. R., & Hersey, P. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.004 · Cited by 205 · see citing works

Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential

Kazanets, A., Shorstova, T., Hilmi, K., Marques, M., & Witcher, M. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.04.001 · Cited by 199 · see citing works

The winding path of protein methylation research: milestones and new frontiers

Murn, J., & Shi, Y. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.35 · Cited by 195 · see citing works

Enhancer of zeste homolog 2 (EZH2) inhibitors

Gulati, N., Béguelin, W., & Giulino-Roth, L. G. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1430795 · Cited by 196 · see citing works

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

Feng, Q. F., Zhang, Z., Shea, M. J., Creighton, C. J., Coarfa, C., Hilsenbeck, S. G., Lanz, R. B., He, B., Wang, L., Fu, X., et al. (2014) · Cell Research · doi:10.1038/cr.2014.71 · Cited by 196 · see citing works

Targeting histone lysine methylation in cancer

McGrath, J. P., & Trojer, P. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.002 · Cited by 188 · see citing works

Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression

Zhou, X., Zang, X., Ponnusamy, M., Masucci, M. V., Tolbert, E. M., Gong, R., Zhao, T. C., Liu, N., Bayliss, G. P., Dworkin, L. D., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015040457 · Cited by 187 · see citing works

Driver mutations of cancer epigenomes

Roy, D. M., Walsh, L. A., & Chan, T. A.-T. (2014) · Protein & Cell · doi:10.1007/s13238-014-0031-6 · Cited by 183 · see citing works

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis

Wang, J., Yu, X., Gong, W., Liu, X., Park, K., Ma, A., Tsai, Y., Shen, Y., Onikubo, T., Pi, W., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00850-x · Cited by 187 · see citing works

Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends

Nepali, K., & Liou, J. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00721-x · Cited by 185 · see citing works

The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat

Kuntz, K. W., Campbell, J. E., Keilhack, H., Pollock, R. M., Knutson, S. K., Porter-Scott, M., Richon, V. M., Sneeringer, C., Wigle, T. J., Allain, C. J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01501 · Cited by 182 · see citing works

PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer

Sato, T., Kaneda, A., Tsuji, S., Isagawa, T., Yamamoto, S., Fujita, T., Yamanaka, R., Tanaka, Y., Nukiwa, T., Márquez, V. E., et al. (2013) · Scientific Reports · doi:10.1038/srep01911 · Cited by 177 · see citing works

EZH2 in normal and malignant hematopoiesis

Lund, K., Adams, P. D., & Copland, M. (2013) · Leukemia · doi:10.1038/leu.2013.288 · Cited by 175 · see citing works

Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia

Cheung, N., Fung, T. K., Zeisig, B. B., Holmes, K. B., Rane, J. K., Mowen, K. A., Finn, M. G., Lenhard, B., Chan, L. C., & So, C. W. E. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.007 · Cited by 173 · see citing works

AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes

Deshpande, A., Deshpande, A., Sinha, A., Chen, L., Chang, J., Cihan, A., Fazio, M., Chen, C., Zhu, N., Koche, R., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.009 · Cited by 172 · see citing works

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models

Chan-Penebre, E., Armstrong, K. A., Drew, A. E., Grassian, A. R., Feldman, I., Knutson, S. K., Kuplast-Barr, K. G., Roche, M. R., Campbell, J., Ho, P. T. C., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0678 · Cited by 172 · see citing works

Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity

Yin, J., Leavenworth, J. W., Li, Y., Luo, Q., Xie, H., Liu, X., Huang, S., Yan, H., Fu, Z., Zhang, L. Y., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521740112 · Cited by 169 · see citing works

Epigenetics of hematopoiesis and hematological malignanciesPreprint

Hu, D., & Shilatifard, A. (2016) · Genes & Development · doi:10.1101/gad.284109.116 · Cited by 167 · see citing works

The central role of EED in the orchestration of polycomb group complexes

Cao, Q., Wang, X., Zhao, M., Yang, R., Malik, R., Qiao, Y., Poliakov, A., Yocum, A. K., Li, Y., Chen, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms4127 · Cited by 167 · see citing works

Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response

Béguelin, W., Teater, M. R., Meydan, C., Hoehn, K. B., Phillip, J. M., Soshnev, A. A., Venturutti, L., Rivas, M. A., Calvo, M. T., Gutierrez, J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.004 · Cited by 161 · see citing works

Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance

Brooun, A., Gajiwala, K. S., Deng, Y., Liu, W., Bolaños, B., Bingham, P., He, Y.-A., Diehl, W. C., Grable, N., Kung, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms11384 · Cited by 164 · see citing works

Harnessing the potential of epigenetic therapy to target solid tumors

Ahuja, N., Easwaran, H., & Baylin, S. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69736 · Cited by 163 · see citing works

Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities

Pierre, R. S., & Kadoch, C. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.02.004 · Cited by 161 · see citing works

Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation

Song, X., Zhang, L., Gao, T., Ye, T., Zhu, Y., Lei, Q., Feng, Q., He, B., Deng, H., & Yu, L. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.04.019 · Cited by 30 · see citing works

Preclinical Characterization of E7438, a Potent, Selective Inhibitor of Protein Methyltransferase EZH2 with Robust Antitumor Activity Against EZH2 Mutated Non-Hodgkin Lymphoma Xenografts in Mice

Keilhack, H., Yokoi, A., Knutson, S. K., Wigle, T. J., Warholic, N. M., Kawano, S., Minoshima, Y., Huang, K., Kuznetsov, G., Kumar, N., et al. (2012) · Blood · doi:10.1182/blood.v120.21.3712.3712 · Cited by 4 · see citing works

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · see citing works

Preclinical Characterization of E7438, a Potent, Selective EZH2 Inhibitor with Robust Antitumor Activity Against EZH2 Mutated NHL Xenografts in Mice

Keilhack, H. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt042.33 · Cited by 3 · see citing works

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma

Knutson, S. K., Kawano, S., Minoshima, Y., Warholic, N. M., Huang, K., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0773 · Cited by 529 · see citing works